Tricida Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Tricida's estimated revenue is currently $10.9M per year.
- Tricida received $100.0M in venture funding in March 2018.
- Tricida's estimated revenue per employee is $139154
- Tricida's total funding is $257M.
- Tricida has 78 Employees.
- Tricida grew their employee count by 44% last year.
- Tricida currently has 13 job openings.
What Is Tricida?
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its late-stage investigational product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). We are led by a management team with an accomplished and proven track record in discovering, developing and commercializing new therapeutics, with extensive experience in building successful companies around strong science and unmet medical needs. We recently completed a successful Initial Public Offering and our stock is listed on the Nasdaq Global Select Market under the symbol TCDA. We are expanding our existing group of exceptionally talented and well-motivated colleagues to develop and commercialize our first-in-class drug candidate, TRC101. Tricida's shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients. Highly Competitive Compensation and Benefitskeywords:Analytics,Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|ZO Skin Health||$54.3M||276||2%|
Tricida, Inc. (NASDAQ:TCDA) marched up 33.35% compared to a 52-week low price of $19.43. The shares were last seen trading 4.18%
BUSINESS WIRE)--Tricida, Inc., (Nasdaq: TCDA) a pharmaceutical company focused on the development and commercialization of its drug
Tricida, Inc. (NASDAQ:TCDA) tinted gains of +0.57% (+0.14 points) to US$24.87. The volume of 0.84 Million shares climbed down over an
|2017-11-09||$57.5M||D||Wellington Management Company LLP||Article|
Tricida Executive Hires
|2016-01-13||Claire Lockey||Chief Development Officer/SVP||Article|
|2017-02-16||Wilhelm Stahl||SVP/Chief Technology Officer||Article|
|2018-01-09||Jeroen van Beek||SVP & Chief Commercial Officer||Article|
|2018-08-02||Dawn Parsell||SVP Clinical Development||Article|
|2019-01-18||Susannah Cantrell||SVP/Chief Commercial Officer||Article|